Unstable Angina Clinical Trial
Official title:
A Phase 2, Multicentre, Double-Blind, Placebo-Controlled, Dose Escalating Trial of the Safety, Pharmacokinetics, and Biological Activity of 3 Consecutive Daily Doses of Serp-1 When Added to Conventional Therapy in Patients With Acute Coronary Syndromes (Non ST-Elevation Myocardial Infarction and/or Unstable Angina)
Verified date | February 2009 |
Source | Viron Therapeutics Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Males and females aged 18-80 years who present with ACS (unstable angina and non ST-elevation MI) defined as one or more episodes of angina lasting at least 5 minutes in the last 24 hours before admission and greater than 0.05 mV of presumed new ST-segment depression in at least 2 contiguous ECG leads OR, angina and per confirmatory angiogram, has been scheduled for percutaneous coronary angioplasty. The primary objective of this study is to evaluate the safety of Serp-1 injection when administered in 3 daily doses to patients undergoing conventional therapy for Acute Coronary Syndrome (ACS) requiring early intervention.
Status | Terminated |
Enrollment | 72 |
Est. completion date | December 2008 |
Est. primary completion date | July 2008 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Established diagnosis of unstable angina or NSTEMI with one or more episodes of angina in the 24 hours before hospital admission - Scheduled for PCI Exclusion Criteria: - CABG within 6 months - Acute ST elevation, eligible for thrombolysis on initial examination - Coronary lesions with total thrombotic occlusions - Current immunosuppressant therapy |
Country | Name | City | State |
---|---|---|---|
Canada | Foothills Medical Center | Calgary | Ontario |
Canada | London Health Sciences Centre | London | Ontario |
Canada | Montreal Heart Institute | Montreal | Quebec |
Canada | University of Ottawa Heart Institute | Ottawa | Ontario |
Canada | Victoria Heart Institute | Vicotria | British Columbia |
United States | University of Florida | Gainesville | Florida |
United States | Spectrum Health | Grand Rapids | Michigan |
United States | Washington Hospital Center | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Viron Therapeutics Inc |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety (Adverse events collected until 6 months post-dose) | |||
Secondary | Inflammatory marker analysis | |||
Secondary | MACE | |||
Secondary | Restenosis at 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05563701 -
Evaluation of the LVivo Image Quality Scoring (IQS)
|
||
Completed |
NCT04097912 -
Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
|
||
Withdrawn |
NCT03906812 -
A Randomized Trial of Telemetry Compared With Unmonitored Floor Admissions in ED Patients With Low-Risk Chest Pain
|
N/A | |
Not yet recruiting |
NCT03610529 -
CardioSenseSystem Compared Study Regarding Efficacy and Safety in the Monitoring of ECG
|
N/A | |
Completed |
NCT01826552 -
Comparison of the Angiographic Result of the Orsiro Hybrid Stent With Resolute Integrity Stent
|
Phase 4 | |
Completed |
NCT01688648 -
Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft
|
N/A | |
Completed |
NCT01709669 -
The Impact of Gratitude on Biology and Behavior in Persons With Heart Disease
|
N/A | |
Completed |
NCT01171404 -
Study Evaluating How Patients With Acute Coronary Syndrome Are Managed During 2 Years After Discharge
|
N/A | |
Completed |
NCT01167582 -
Myocardial Ischemia and Transfusion Pilot
|
Phase 3 | |
Completed |
NCT01020383 -
Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients
|
Phase 2 | |
Completed |
NCT00449826 -
Risk Stratification of Non ST Elevation ACS With Computed Tomographic Angiography (REACT)
|
N/A | |
Terminated |
NCT00355992 -
The Ischemia Modified Albumin In Diagnosing Ischemic New Events
|
N/A | |
Completed |
NCT00263263 -
RRISC Study: Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent.
|
Phase 2 | |
Active, not recruiting |
NCT04929496 -
Physiology as Guidance to Evaluate the Direct Impact of Coronary Lesion Treatment: The PREDICT Study
|
N/A | |
Completed |
NCT03103620 -
Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
|
||
Completed |
NCT04648306 -
Restore EF Observational Study
|
||
Not yet recruiting |
NCT03266289 -
Evaluation of Short Term Outcome of Different Bifurcation Stenting Techniques at Assuit University Cath. Lab
|
N/A | |
Not yet recruiting |
NCT04403048 -
Drug Coated Balloon for Side Branch Treatment vs. Conventional Approach in True Bifurcation Coronary Disease: PRO-DAVID
|
N/A | |
Recruiting |
NCT02748603 -
Appropriateness of Coronary Angioplasty in PAtients With isCHEmic Heart Disease
|
N/A | |
Completed |
NCT01774838 -
Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome
|
Phase 3 |